<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> (<z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e>) is an uncommon subtype of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>); it is considered to have a poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> were seen at the University of Texas-M.D </plain></SENT>
<SENT sid="2" pm="."><plain>Anderson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center (UT-MDACC) </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-five patients (50%) had a history of myelodysplatic syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), compared with 41% in our control group (patients with other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> subtypes) (P=0.08) </plain></SENT>
<SENT sid="4" pm="."><plain>Poor-risk cytogenetics were more common in patients with <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> (61% versus 38%, P=0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Complete remission rates were 62% for patients with <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e>, comparing with 58% for the control group (P=0.35) </plain></SENT>
<SENT sid="6" pm="."><plain>Median disease free survival (DFS) for patients with <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> was 32 weeks, versus 49 weeks for the control group (P=0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Median overall survival (OS) of patients with <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> was 36 weeks, compared with 43 weeks for the control group (P=0.60) </plain></SENT>
<SENT sid="8" pm="."><plain>On multivariate analysis for DFS and OS, <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> was not an independent risk factor </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> is commonly associated with a previous diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and poor-risk karyotype </plain></SENT>
<SENT sid="10" pm="."><plain>The diagnosis of <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> prognostic factors </plain></SENT>
</text></document>